Showing results (321-330 of 753) with videos related to
Sort By:
Pageof 76
Journal of Neuro-Oncology|July 6, 2013
Retrospective study of pemetrexed as salvage therapy for central nervous system lymphomaJun-Ping Zhang, Eudocia Q Lee, Lakshmi Nayak, et al.Scientific Reports|September 10, 2021
Genomic landscape of gliosarcoma: distinguishing features and targetable alterationsMark M Zaki, Leila A Mashouf, Eleanor Woodward, et al.Neuro-Oncology|June 1, 2023
A genomic score to predict local control among patients with brain metastases managed with radiationNayan Lamba, Daniel N Cagney, Paul J Catalano, et al.The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO groupNancy U Lin, Jeffrey S Wefel, Eudocia Q Lee, et al.Neuro-Oncology|February 7, 2014
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO reviewThomas Kaley, Igor Barani, Marc Chamberlain, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma PatientsEudocia Q Lee, Thomas J Kaley, Dan G Duda, et al.Neuro-Oncology|August 22, 2022
National-level overall survival patterns for molecularly-defined diffuse glioma types in the United StatesQuinn T Ostrom, Madison L Shoaf, Gino Cioffi, et al.Epilepsy Research|April 3, 2014
Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging studyJong Woo Lee, Andrew D Norden, Keith L Ligon, et al.Neuro-Oncology|November 25, 2024
Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisHia S Ghosh, Ruchit V Patel, Elizabeth B Claus, et al.Pageof 76